AstraZeneca Asthma Drug Fasenra Receives FDA Approval
15 Novembre 2017 - 8:53AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Wednesday that its Fasenra drug
for the treatment of asthma has received approval from the U.S.
Food and Drug Administration based on the results of a phase 3
program.
The pharmaceutical company said the program showed a reduction
of up to 51% in the annual asthma exacerbation rate, significant
improvement in lung function, and allowed for a median 75%
reduction in steroid use in patients.
The FDA approved the drug for patients 12 years and older, with
severe asthma driven by eosinophilic inflammation, AstraZeneca
reported.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 15, 2017 02:38 ET (07:38 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
